Navigation Links
Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
Date:7/24/2009

SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its underwriters fully exercised their overallotment option to purchase an additional 1,500,000 shares of its common stock in connection with its previously announced public offering that priced on July 23, 2009. Including the overallotment shares purchased, the company sold 11,500,000 shares at a public offering price of $7.50 per share, resulting in expected net proceeds to the company of approximately $81.6 million (after payment of the underwriting discounts and commissions and estimated expenses).

Leerink Swann LLC acted as sole book-running manager for the offering. Lazard Capital Markets LLC, Canaccord Adams Inc., JMP Securities LLC and Natixis Bleichroeder Inc. acted as co-managers for the offering.

The securities described above are being offered by Orexigen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found athttp://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... third U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN site. ... 483 was issued. This inspection was conducted as part of a routine Bioresearch ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kapstone Medical ... years of successes helping medical technology companies and inventors develop and safeguard their latest ... full-service national engineering firm with a portfolio of clients in the United States and ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, ... modular downlights designed to stay tightly sealed and perform efficiently for years. The ... wet location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; ...
(Date:8/14/2017)... ... August 14, 2017 , ... Every year, millions ... in the antibody community have recently come together to address this antibody crisis ... laboratory. , The team at Thermo Fisher Scientific has ...
Breaking Biology Technology:
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
Breaking Biology News(10 mins):